Patel Asha R, Turner Maria L, Baird Kristin, Gea-Banacloche Juan, Mitchell Sandra, Pavletic Steven Z, Wise Barbara, Cowen Edward W
Dermatology Branch, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Biol Blood Marrow Transplant. 2009 Mar;15(3):370-6. doi: 10.1016/j.bbmt.2008.12.491.
Systemic fungal infections pose a significant risk to patients following allogeneic hematopoietic cell transplantation (alloHCT). Voriconazole (Vfend, Pfizer) is an oral second-generation triazole antifungal agent that offers a broad spectrum of coverage against fungal species and is frequently utilized in the post-HCT setting. Herein, we describe 5 patients who were initially believed to be experiencing a flare of cutaneous chronic graft-versus-host disease (cGVHD), but who were actually exhibiting phototoxicity caused by voriconazole. A high index of suspicion for this adverse reaction in the post-alloHCT setting will prevent misdiagnosis and avoid inappropriate therapy for cGVHD.
异基因造血细胞移植（alloHCT）后，系统性真菌感染对患者构成重大风险。伏立康唑（威凡，辉瑞公司）是一种口服第二代三唑类抗真菌药物，对多种真菌具有广泛的覆盖范围，常用于alloHCT后的治疗。在此，我们描述了5例最初被认为是皮肤慢性移植物抗宿主病（cGVHD）发作，但实际上是由伏立康唑引起光毒性的患者。在alloHCT后高度怀疑这种不良反应将可防止误诊，并避免对cGVHD进行不适当的治疗。
